HENAN SUNLAKE ENTERPRISE CORPORATION
Free supplier Enterprise Certification
- Free
supplier - 9th
years
Free supplier Enterprise Certification
Product Certification&
Enterprise Certification
Country: 
China (Mainland)
Business Type:Trading Company
Tel: +86-371- 86259723
Tel: 17734809689
Tel: 17734809689
Tel: 86-371-86259723
Tel: 17734809689
Tel: 17734809689
Mobile: 17734809689
Tel: +86-371- 86259723
Fax: +86-371- 86259723
Province/state: HENAN
City: ZHENGZHOU
Street: Mingmen International Center, NO.222 Dongming Road,Zhengzhou,Henan,China
MaxCard:
Contact Suppliers
CAS NO.132810-10-7
| Blonanserin Basic information |
| Product Name: | Blonanserin |
| Synonyms: | CYCLOOCTA[B]PYRIDINE, 2-(4-ETHYL-1-PIPERAZINYL)-4-(4-FLUOROPHENYL)-5,6,7,8,9,10-HEXAHYDRO-;Blonanserin;AD 5423;2-(4-Ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine;2-(4-Ethylpiperazin-1-yl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine;Lonasen;Blonansarin –;Blonanserin, AD-5423, Lonasen |
| CAS: | 132810-10-7 |
| MF: | C23H30FN3 |
| MW: | 367.5028032 |
| EINECS: | |
| Product Categories: | APIs;Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals |
| Mol File: | 132810-10-7.mol |
|
|
|
| Blonanserin Chemical Properties |
| mp | 117-119°C |
| storage temp. | Refrigerator |
| Blonanserin Usage And Synthesis |
| Outline | This product is a serotonin and dopamine antagonist (SDA), it is a second-generation atypical antipsychotic drugs, and has a considerable dopamine D2 receptor blocking action as haloperidol , it also has a strong 5-HT2A blocking effect, the selectivity on both receptors is stronger than other antipsychotics. It displays fewer extrapyramidal response side effects than conventional antipsychotics on the market . It is developed and sold by Sumitomo Pharmaceutical Co., Ltd. of Japan. Listing: April 2008 in Japan. |
| Synthesis method |
Fluorobenzoate condensates with acetonitrile to get fluorobenzoyl acetonitrile, prepared in polyphosphoric acid by the reaction of 3- (4-fluorophenyl) -3-oxo-propionamide, and cyclooctanone cyclization of 4- (4-fluorophenyl) -5,6,7,8,9,10-hexahydro-cyclooctane and [b] pyridin -2 (1H) - one, and recrystallized from benzene dichloride Lin acid dichloride with N- ethylpiperazine nucleophilic substitution to give antipsychotic blonanserin, the overall yield is about 42%. Author: Junfang Wang, Xiaomei Wang , Zhefeng Wang , Huilin Shi Author unit: Shanghai Institute of Pharmaceutical Industry Journal Name: Chinese Journal of Pharmaceuticals 2009 40 (4) |
| Atypical antipsychotic drugs |
Schizophrenia is a common psychiatric disease, since the early 1950s, for the discovery of antipsychotic effects of chiorpromazinum. Schizophrenia has been treated with drugs. According to receptor blocking actions, the commonly used antipsychotics are divided into two categories, naming the typical and atypical: typical antipsychotics are represented by chlorpromazine and haloperidol . The main mechanism is blocking dopamine receptors, it has a good effect on positive symptoms of schizophrenia (hallucinations, delusions, agitation, impulsive behavior, etc.) . Meanwhile extrapyramidal effects (EPS) are common, while the effects for negative symptoms (apathy, poverty of thought, will decline, etc.) are poor, while atypical antipsychotics show a wider spectrum for the treatment of negative symptoms better than traditional medicine, and it is safe, with more mild side effects, the dosage is smaller, there have been many more advanced forms, which greatly improve patient compliance, representative drugs include clozapine, risperidone, olanzapine . Double-blind clinical trials for 8 weeks for blonanserin comparison with haloperidol shown, 263 patients with schizophrenia were involved. 8-24mg / day blonanserin is at least effective as 4-12mg / day of haloperidol, it can improve the final grade improvement rate(FGIR) score (at least two drugs in patients with moderate improvement rate of 61.2% and 51.3%, respectively), less incidence of extrapyramidal side effects (52.7% and 75.4%). The above information is edited by the chemicalbook of Tian Ye. |
| China Patent Information |
January 2008 blonanserin was developed and sold by Sumitomo Pharmaceutical Co., Ltd. of Japan. This product was compound patent in 1989 . The patent has expired. At present, the domestic product is not imported, according to the "Patent Law" and "Regulations on Administrative Protection Drugs" , the drug patent risk does not exist in China, it does not have the conditions of application for administrative protection. |
| Application | Mental |
| Chemical Properties | Pale Yellow Solid |
| Usage | Blonanserin is a novel atypical antipsychotic agent with potent dopamine D2 (Ki, 14.8 nM) and serotonin 5-HT2(Ki, 3.98 nM) receptors antagonist properties. |
| Usage | A 5-HT2 Serotonin receptor and D2 Dopamine receptor antagonist, used as an antipsychotic. |
Synonyms 2-(4-Ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta(b)pyridine
CAS NO:132810-10-7
Molecular Formula: C23H30FN3
Molecular Weight: 367.502
Relative density: 1.095g/cm3
Specifications:The enterprise standard =98%
Package:5kg/TIN,25kg/Drum
